V/Q SPECT for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
VA Ann Arbor Healthcare System, Ann Arbor, MINon-Small Cell Lung CancerV/Q SPECT - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is designed to see if using a PET scan and a perfusion scan before and during radiation therapy for lung cancer helps to predict how well the treatment works and how well the lung functions during treatment.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 2 Secondary · Reporting Duration: Up to 60 months

Week 6
Comparison of delivered dose to dose that would have been administered using the criteria described in protocol UMCC 2007.123 (NCT01190527)
The number of patients for whom treatment is feasible.
Up to 24 months
The number of patients that experience grade 2 or greater lung toxicity
Up to 3 months
The number of patients that experience grade 2 or greater esophageal toxicity
Up to 60 months
Overall survival time
Time to local progression

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Response-driven Adaptive RT
1 of 1

Experimental Treatment

49 Total Participants · 1 Treatment Group

Primary Treatment: V/Q SPECT · No Placebo Group · N/A

Response-driven Adaptive RTExperimental Group · 6 Interventions: FDG-PET, Carboplatin, Durvalumab, V/Q SPECT, Response-driven Adaptive Radiation Therapy, Paclitaxel · Intervention Types: Device, Drug, Drug, Device, Radiation, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FDG-PET
2008
Completed Phase 4
~520
Carboplatin
FDA approved
Durvalumab
FDA approved
Paclitaxel
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 months

Who is running the clinical trial?

University of Michigan Rogel Cancer CenterLead Sponsor
270 Previous Clinical Trials
18,106 Total Patients Enrolled
Shruti Jolly, M.D.Principal InvestigatorUniversity of Michigan Rogel Cancer Center
3 Previous Clinical Trials
190 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What prior experimentation has been conducted with V/Q SPECT?

"Currently, there exist 1435 studies exploring the efficacy of V/Q SPECT. Of these trials, 365 are in Phase 3 development and 74833 sites across Shanghai are hosting them." - Anonymous Online Contributor

Unverified Answer

How many participants are currently being accepted for this research trial?

"Unfortunately, this research project has closed its doors to new participants. The trial was first uploaded on January 14th 2016 and the latest update happened on December 17th 2021. If you are seeking other trials, there are 1365 studies for carcinoma non-small cell lung cancer patients actively recruiting and 1435 V/Q SPECT clinical trials searching for volunteers." - Anonymous Online Contributor

Unverified Answer

How is V/Q SPECT customarily deployed in clinical practice?

"V/Q SPECT has traditionally been used for palliative care, but it can also be employed to treat a range of medical conditions such as malignant peritoneal neoplasm in newly diagnosed patients." - Anonymous Online Contributor

Unverified Answer

Are there available slots for participants in this clinical trial?

"This clinical trial, initially posted on January 14th 2016 and last updated December 17th 2021 is no longer recruiting according to the data hosted by clinicaltrials.gov. Nonetheless, there are presently 2,800 other medical studies actively seeking out participants." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.